vTv Therapeutics Inc.
corporate_fare Company Profile
vTv Therapeutics Inc. (NASDAQ:VTVT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 10 items for VTVT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-10-07, rated 7/10. Across its 10 most recent items scored 7 or higher, the top rating is 9/10, with 7 rated 8 or above. Recent SEC coverage for VTVT spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- FDA Grants Orphan Drug Designation to vTv's HPPD for Sickle Cell Disease
- vTv Therapeutics Swings to $1.05/Shr Loss in Q2 After Q1 Profit
- vTv Therapeutics Stockholders Express Significant Dissent on Director Elections and Executive Pay
- vTv Therapeutics Expands ATM Program to Full $47.5M Capacity, Allowing Significant Potential Dilution
- vTv Therapeutics Reports Strong Q1 Profit and Boosted Cash from Licensing Deals
Financial Snapshot
Short Interest & Short Volume
8.21 days to coverFINRA reported short interest of 145,417 shares in VTVT as of the October 30, 2026 settlement, a 1.4% increase from the prior period — about 8.2 days to cover at its recent average daily volume. On November 20, 2026, 68.3% of VTVT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.